- Policy
- The MSI invests ₩420 billion to bio-based technologies
- by Lee, Jeong-Hwan Jan 9, 2020 06:42am
- The government will invest &8361;420 billion to foster bio as a next-generation growth industry and invests &8361;61.4 billion in finding and verifying new drugs. The budget increased by 10.1% compared to the previous year for the development of bio-based technologies. New drugs, medical devices, brain research, and bio-big data are the are
- Policy
- ATP-based reduction on immunosuppressant Certican
- by Kim, Jung-Ju Jan 9, 2020 06:24am
- Price of Novartis’ immunosuppressant Certican (everolimus), still in prolonged pricing reduction cancellation litigation with the government, would be reduced based on actual transaction price (ATP) survey result. The pricing reduction on Certican would be enforced after the ongoing litigation reaches its final decision as it still has admi
- Policy
- Reevaluation to first review underperforming drug
- by Kim, Jung-Ju Jan 8, 2020 06:19am
- The government reaffirmed the listed drug reevaluation subject would prioritize drugs with clinical efficacy underperforming than initially expected. Gradually conducted on all subjected drugs, actions following up the reevaluation, such as pricing reduction or reimbursed indication revocation or reduction on drug not reaching expected e
- Policy
- Generic pricing should be at original’s 40%-45%
- by Lee, Hye-Kyung Jan 8, 2020 06:17am
- The national insurer’s research result claims the volume of generic would increase up to 73 percent to 82 percent if the use of generic is promoted, if the present lump-sum generic pricing reduction is brought down to 40 percent or 45 percent of the original price before patent expiration. Currently, the lump-sum pricing reduction drops generic
- Policy
- China's "New Law" tightens safety and quality management
- by Kim, Jung-Ju Jan 8, 2020 06:15am
- China is to reinforce overall pharmaceutical management and monitoring regulation covering from pharmaceutical production, launch, clinical trial to counterfeit drug. The so-called ‘New Drug Administration Law’ would mainly focus on safety and quality. China’s National Medical Products Administration (NMPA) had taken the revised law i
- Policy
- Derazantinib-Tecentriq trial approved in Korea
- by Lee, Jeong-Hwan Jan 7, 2020 06:28am
- A global clinical trial to test a combination therapy of anticancer treatment derazantinib and immunotherapy Tecentriq (atezolizumab) was approved in Korea to treat patients with urothelial cancer. The clinical trial has been put together as derazantinib developer Basilea Pharmaceutica and Tecentriq developer Roche have signed a collabor
- Policy
- Eliquis' price cut has been reserved
- by Kim, Jung-Ju Jan 6, 2020 11:00pm
- Against the government's lower policy price cut, the former drug price of BMS Eliquis (Apixaban), which is appealing to the court, will be temporarily held. Currently in progress at the Seoul High Court, if it is terminated, additional price cuts are scheduled for June 1st. The Seoul High Court's 9th Executive (2019-Ah1617) decided to t
- Policy
- Industry speculating on special clause for IMD
- by Lee, Jeong-Hwan Jan 6, 2020 06:22am
- While the government’s announcement on the revised drug pricing regulation has been delayed, the pharmaceutical industry is seemingly speculating on a possible new special clause of the regulation to exempt incrementally modified drug (IMD) with recognized non-obviousness. The industry predicts the government is more likely to make an exce
- Policy
- Early market entry of Gabsmet salt-modifying drugs are noted
- by Lee, Tak-Sun Jan 6, 2020 06:21am
- The salt-modifying drug 'Galvusmet', a DPP-4 inhibitory diabetes drug, applied for approval for the first time in Korea on the 24th of last month. It is therefore noteworthy whether it will be released to the market early. According to the MFDS on the 24th, Vildagliptin HCl-Metformin HCl combination was applied for the first time to the pa
- Policy
- Announcement of drug price reform is delayed
- by Kim, Jung-Ju Jan 4, 2020 08:47pm
- The reform of the drug price system, which the government plans to announce last month, is delayed somewhat. The pharmaceutical industry is all on edge because of the reorganization of generic drug prices, improved risk-sharing contract (RSA), economic exemption system, and insurance policy supplementary agreement (sub-contract). ◆Generic
